REPARE THERAPEUTICS INC (RPTX) Stock Price, Quote, News and Overview
NASDAQ:RPTX - Nasdaq - US7602731025 - Common Stock - Currency: USD
RPTX Quote, Performance and Key Statistics
1.25
-0.08 (-6.02%)
The current stock price of RPTX is 1.25 USD. In the past month the price increased by 16.82%. In the past year, price decreased by -60.94%.
RPTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About RPTX
Company Profile
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 129 full-time employees. The company went IPO on 2020-06-19. The firm utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Company Info
REPARE THERAPEUTICS INC
7210 Frederick-Banting, Suite 100
ST-LAURENT QUEBEC H4S 2A1 CA
CEO: Lloyd M. Segal
Employees: 179
Company Website: https://www.reparerx.com/
Investor Relations: http://ir.reparerx.com/
Phone: 18574127018
REPARE THERAPEUTICS INC / RPTX FAQ
What is the stock price of REPARE THERAPEUTICS INC today?
The current stock price of RPTX is 1.25 USD. The price decreased by -6.02% in the last trading session.
What is the ticker symbol for REPARE THERAPEUTICS INC stock?
The exchange symbol of REPARE THERAPEUTICS INC is RPTX and it is listed on the Nasdaq exchange.
On which exchange is RPTX stock listed?
RPTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REPARE THERAPEUTICS INC stock?
11 analysts have analysed RPTX and the average price target is 6.63 USD. This implies a price increase of 430.4% is expected in the next year compared to the current price of 1.25. Check the REPARE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REPARE THERAPEUTICS INC worth?
REPARE THERAPEUTICS INC (RPTX) has a market capitalization of 53.14M USD. This makes RPTX a Micro Cap stock.
How many employees does REPARE THERAPEUTICS INC have?
REPARE THERAPEUTICS INC (RPTX) currently has 179 employees.
What are the support and resistance levels for REPARE THERAPEUTICS INC (RPTX) stock?
REPARE THERAPEUTICS INC (RPTX) has a support level at 1.25 and a resistance level at 1.38. Check the full technical report for a detailed analysis of RPTX support and resistance levels.
Is REPARE THERAPEUTICS INC (RPTX) expected to grow?
The Revenue of REPARE THERAPEUTICS INC (RPTX) is expected to decline by -83.4% in the next year. Check the estimates tab for more information on the RPTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy REPARE THERAPEUTICS INC (RPTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RPTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RPTX, evaluating the profitability, health, valuation and growth aspects
- REPARE THERAPEUTICS INC (RPTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REPARE THERAPEUTICS INC (RPTX) Sales and EPS estimates to see what analysts future expectations are.
- REPARE THERAPEUTICS INC (RPTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REPARE THERAPEUTICS INC (RPTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- REPARE THERAPEUTICS INC (RPTX) Stock Chart to make your own analysis
- REPARE THERAPEUTICS INC (RPTX) Latest news and press-releases to stay up to date.
Does REPARE THERAPEUTICS INC (RPTX) stock pay dividends?
RPTX does not pay a dividend.
When does REPARE THERAPEUTICS INC (RPTX) report earnings?
REPARE THERAPEUTICS INC (RPTX) will report earnings on 2025-05-13, after the market close.
What is the Price/Earnings (PE) ratio of REPARE THERAPEUTICS INC (RPTX)?
REPARE THERAPEUTICS INC (RPTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
What is the Short Interest ratio of REPARE THERAPEUTICS INC (RPTX) stock?
The outstanding short interest for REPARE THERAPEUTICS INC (RPTX) is 2.06% of its float. Check the ownership tab for more information on the RPTX short interest.
RPTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RPTX. When comparing the yearly performance of all stocks, RPTX is a bad performer in the overall market: 83.37% of all stocks are doing better.
RPTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RPTX. RPTX has a great financial health rating, but its profitability evaluates not so good.
RPTX Financial Highlights
Over the last trailing twelve months RPTX reported a non-GAAP Earnings per Share(EPS) of -2. The EPS increased by 10.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.98% | ||
| ROE | -56.04% | ||
| Debt/Equity | 0 |
RPTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to RPTX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -7.36% and a revenue growth -83.4% for RPTX